Benitec Biopharma Inc.
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Nov 12, 2026 (17 days)
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 23, 2026 | Raymond James | initiate | — → Outperform | — | 54% |
| Sep 15, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jul 28, 2026 | Wedbush | initiate | — → Outperform | — | 58% |
| May 12, 2026 | Evercore ISI Group | initiate | — → Outperform | — | 58% |
| Mar 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Nov 24, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $32 | 44% |
| Nov 4, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $35 | 44% |
| Nov 4, 2025 | Citizens | maintain | Market Outperform → Market Outperform | $22 | 47% |
| Sep 24, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $20 | 53% |
| Sep 16, 2025 | Oppenheimer | maintain | Outperform → Outperform | $29 | 52% |
| May 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $28 | 44% |
| May 15, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $20 | 53% |
| Apr 10, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $20 | 53% |
| Mar 24, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $28 | 44% |
| Mar 18, 2025 | Citizens Capital Markets | reiterate | Market Outperform → Market Outperform | $18 | 49% |
| Feb 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $28 | 44% |
| Dec 13, 2024 | Baird | initiate | — → Outperform | $30 | 55% |
| Dec 3, 2024 | Guggenheim | reiterate | Buy → Buy | $17 | 52% |
| Jul 22, 2024 | Leerink Partners | initiate | — → Outperform | $13 | 51% |
| Jun 13, 2024 | Piper Sandler | initiate | — → Overweight | $30 | 54% |
| Apr 22, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $16 | 53% |
| Feb 15, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $10 | 53% |
| Jan 24, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $8 | 53% |
| Sep 26, 2023 | JMP Securities | maintain | Market Outperform → Market Outperform | $6 | 53% |
No cross-platform signals in the last 90 days